Abstract
We treated 10 cases of chronic rhinosinusitis with nasal polyps (CRSwNP) with dupilumab, an anti-IL-4/IL-13 antibody receptor drug, and examined the longitudinal changes in the levels of type 2 inflammatory markers, such as the fraction of exhaled nitric oxide (FeNO), blood eosinophil count, and serum total IgE before and after 24 weeks of dupilumab administration.
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
